Dallas, Texas 02/05/2014 (FINANCIALSTRENDS) – The recent Vical Incorporated (NASDAQ:VICL)’s phase 3 trial failure has lead to speculations that what’s up with Vical. Recently its lead product that is Allovectin 7 failed clinical trials but everybody was surprised after a 25 cents jump and the share price closed at $1.59.
One of the best things about the company is that it has got a strong insider trading and as a result there are many insiders who are now switching from selling to buying and there is this cluster buying that is happening with the help of multiple executives. There are some unusual large tickets that are being booked and this stock has got a strong history of getting it right scenario. To prove this we can discuss the case of trading that happened in the 1st week of January’2014 when a total of four insiders bought about 580,000 shares of Vical. The total investment was believed to be around $ 823,000.
Something about Vical Incorporated (NASDAQ:VICL)
Vical Incorporated (NASDAQ:VICL) is basically a research and development company that deal with different bio pharmaceutical products that are based on DNA also called as Deoxyribonucleic acid delivery technologies. All of the products that are being developed by the company are aimed at preventing and treating life threatening and serious diseases.
The company has mainly three verticals and those are infectious disease and cancer, Phase 3 clinical trials that includes Allovectin immunotherapeutic and a dedicated preclinical program. Company also develops drugs that are beneficial during infection before and after the pregnancy. The recent buying in this stock can be seen as a return of the positive sentiment coming back to American markets and moreover recent positive comments made by FED are acting as music to the air for those who bought this share in the month of January 2014.